Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets In Clopidogrel (Plavix(R)) Non-Responders Portola Pharmaceuticals, a biopharmaceutical company developing innovative
drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)).
Source: www.medicalnewstoday.comMerck Serono Launches Expansion Of Flagship Biotech Center To Meet Growing Patient Needs Merck Serono, the division for innovative pharmaceuticals of Merck KGaA, Darmstadt, Germany, today held a cornerstone ceremony at the Merck Serono Biotech Center (MSBC), its production site in Corsier-sur-Vevey, Switzerland, to mark the expansion of the site.
Source: www.medicalnewstoday.comPSN Editor's Award Received By Rutgers College Of Nursing Professor And Her 2 Students The American Society of Plastic Surgical Nurses presented its Plastic Surgical Nurses (PSN) Editor's Award to Marlene Rankin, a Rutgers College of Nursing faculty member, and her two co-authors, during its annual convention in Chicago Nov. 1.
Source: www.medicalnewstoday.comNovexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial In Hospital Patients With Complicated Urinary Tract Infections Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical trials.
Source: www.medicalnewstoday.comViroPharma Announces Presentation Of Cinryze(TM) Data In Acute Treatment Of Hereditary Angioedema ViroPharma Incorporated (Nasdaq: VPHM) announced the presentation of data from its ongoing, open-label study, showing that in this study Cinryze(TM) C1 inhibitor therapy successfully treated all types of acute hereditary angioedema (HAE) attacks seen in the study through the date of analysis. Patients suffering acute attacks of HAE who were treated with Cinryze experienced improvement in symptoms at a median time of 30 minutes post treatment.
Source: www.medicalnewstoday.comMetabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982 Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new
medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008.
Source: www.medicalnewstoday.comCircum-menopausal Changes In Women's Face Preferences Here we show that changes in hormone levels during menopause affect women's attractiveness judgments. Post-menopausal women demonstrated stronger preferences for femininity in women's faces than pre-menopausal women did.
Source: www.medicalnewstoday.comCatholic Bishops At Conference Adopt Declaration Against Freedom Of Choice Act Catholic bishops on Tuesday at the U.S. Conference of Catholic Bishops General Assembly approved a statement saying that if the Democratic-controlled Congress and President-elect Barack Obama enact the
Source: www.medicalnewstoday.comAlzheimer's-Associated Changes In Mouse Brains Induced By Common Anesthetic For the first time researchers have shown that a commonly used anesthetic can produce changes associated with Alzheimer's disease in the brains of living mammals, confirming previous laboratory studies. In their Annals of Neurology report, which has received early online release, a team of Massachusetts General Hospital (MGH) investigators shows how administration of the gas isoflurane can lead to generation of the toxic amyloid-beta (A-beta) protein in the brains of mice.
Source: www.medicalnewstoday.comTestosterone Effective In Female Sexual Dysfunction; BioSante Conducting Long-Term Safety Study Of LibiGel(R) In FSD BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company focused on developing products for female sexual
health, menopause, contraception, and male hypogonadism, commented today on a new publication reporting on the efficacy of testosterone in the treatment of Female Sexual Dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD) in menopausal women.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
